Material Event (Form 8-K)

On May 6, 2021, ORIC Pharmaceuticals, Inc. (the "Company") entered into an Open Market Sale Agreement^SM (the "Sales Agreement") with Jefferies LLC ("Jefferies") to sell shares of the Company's common stock, par value $0.0001 per share (the "Shares"), from time to time, through an "at the market offering" program under which Jefferies acts as sales agent. The Shares are issued pursuant to the Company's effective shelf registration statement on Form S-3ASR(File No. 333-277829),filed on March 11, 2024, which became automatically effective upon filing with the Securities and Exchange Commission (the "SEC"). On March 11, 2024, the Company filed a prospectus supplement (the "2024 Prospectus Supplement") with the SEC in connection with the offer and sale of up to $200.0 million of Shares pursuant to the Sales Agreement. As of February 23, 2026, the Company had sold 13,478,432 of Shares for gross proceeds of approximately $139.7 million, before deducting commissions to Jefferies and other expenses, under the 2024 Prospectus Supplement.

On February 26, 2026, the Company filed a prospectus supplement with the SEC in connection with the offer and sale of up to $200.0 million of Shares pursuant to the Sales Agreement (the "2026 Prospectus Supplement"). No further sales of shares will be made under the 2024 Prospectus Supplement.

The legal opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation, relating to the Shares being offered in connection with the 2026 Prospectus Supplement is filed as Exhibit 5.1 to this Current Report on Form 8-K.

This Current Report shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.